Hetero has announced that it has received manufacturing and marketing approval for remdesivir from the DCGI for treatment against COVID-19. The drug will be marketed under the brand name ‘COVIFOR’ in India.
Dr B Partha Saradhi Reddy, Chairman, Hetero Group of Companies said, “In the light of increasing COVID-19 cases in India, the approval of ‘COVIFOR’ (remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country. We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against COVID-19.”
According to the statement of the company, “Remdesivir has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease. COVIFOR will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.”
A licensing agreement with Gilead Sciences has been signed to expand access to COVID-19 treatment in low and middle-income countries.
The company further stated that the product named ‘COVIFOR’ will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.
For patients suffering from severe symptoms of the diseases, Remdesivir has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children.
